Becton, Dickinson and Company (BDX)
| Market Cap | 56.11B |
| Revenue (ttm) | 21.39B |
| Net Income (ttm) | 1.59B |
| Shares Out | 286.63M |
| EPS (ttm) | 5.47 |
| PE Ratio | 35.77 |
| Forward PE | 13.50 |
| Dividend | $4.16 (2.13%) |
| Ex-Dividend Date | Sep 8, 2025 |
| Volume | 725,269 |
| Open | 195.21 |
| Previous Close | 194.96 |
| Day's Range | 193.94 - 196.18 |
| 52-Week Range | 163.33 - 251.99 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 222.75 (+13.78%) |
| Earnings Date | Aug 7, 2025 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]
Financial Performance
In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $222.75, which is an increase of 13.78% from the latest price.
News
Heartland's 3 Tactical Q2 Moves: Trimming Risk, Harvesting Losses, And Raising Cash
We remain patient and opportunistic, raising cash to capitalize on future volatility and focusing on stocks meeting our 10 Principles of Value Investing™. We initiated a position in Applied Materials,...
Becton Dickinson Q3 Beats Estimates On Medical Device Boom
As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company BDX are reporting robust financial performances that highlight their resilience a...
Becton, Dickinson and Company (BDX) Q3 2025 Earnings Call Transcript
Becton, Dickinson and Company (NYSE:BDX) Q3 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Christopher J. DelOrefice - Executive VP & CFO Greg Rodetis - Senior VP, Treasurer & Head...
Becton Dickinson joins peer in raising annual profit forecast after results beat
Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.
BD Reports Third Quarter Fiscal 2025 Financial Results
Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively GAAP and adjusted gross margin up 160 basis ...
BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories
FRANKLIN LAKES, N.J. , Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC...
BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care
FRANKLIN LAKES, N.J. , Aug. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest more than $35 million a...
BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home
New FDA Submission Includes Self-Collection Swab and High-Tech Laboratory Robotics that Report More High-Risk HPV Strains Than Any Other Test FRANKLIN LAKES, N.J. , July 31, 2025 /PRNewswire/ -- BD (B...
BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test
New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J. , July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading ...
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 20...
22 Dividend Kings At Discounted Valuations
Dividend kings can offer reliable income growth and capital appreciation, making them attractive for long-term investors. During our screening today, we have 22 dividend kings trading at what could be...
20 Kiplinger July Dividend Favorites: No Cigars
Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d...
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J. , July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination produ...
BD Board Declares Dividend
FRANKLIN LAKES, N.J. , July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...
Becton Dickinson gets its spinoff deal, but the stock is still falling
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to ...
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment
FRANKLIN LAKES, N.J. , July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin ha...
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.
Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now
Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until ...
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Becton, Dickinson and Company (NYSE:BDX) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Cal...
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividen...